Mirvetuximab soravtansine-gynx shows a significant benefit over chemotherapy in women with platinum-resistant, FRα-positive ovarian cancer

 The recently completed phase III MIRASOL study, indicating that treatment with "mirvetuximab soravtansine-gynx, compared with chemotherapy, was associated with significant benefits in terms of progression-free survival (PFS), objective response, and overall survival (OS)" in ovarian cancer patients.  Platinum-resistant ovarian cancer has few targeted treatments available, thus "mirvetuximab soravtansine-gynx appears to be capable of inducing responses and improving survival.."  

To read more about this study, click here. 

Source mentioned: 

Moore KN. Angelergues A, Konecny GE, et al. for Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med 2023;389:2162-2174.

Reconnecting to life after cancer: permission to heal (webinar)

The National Coalition for Cancer Survivorship (NCCS) has recently launched the webinar, "Reconnecting to Life After Cancer: Permission to Heal", presented by a holistic cancer coach and cancer survivor.  The webinar will include discussions about "the evolutionary function of both positive and negative emotions, understand that emotions offer data, and begin to practice awareness to empower you to respond-instead of react-to life."   

Click here to watch the video, or watch on YouTube.

First study to demonstrate that PD1 immune checkpoint blockade may yield clinical-pathologic regression in some patients with high-risk oral precancerous disease

 Findings of what is believed to be the first non-randomized study of immune checkpoint blockade in parents with high-risk oral precancer, was published in JAMA Oncology.  

A next step would be to consider a larger, precision immunotherapy randomized study favouring cancer-free survival (CFS) as a primary outcome and stratified by prior history of early-stage treated OSCC and 9p21.3 loss according to Dr. Glenn J. Hanna of the Department of Medical Oncology, Center for Head & Neck Oncology, Dana-Farber Cancer Institute, Harvard Medical School in Boston, MA, US, and colleagues who published their findings on 16 November 2023 in the JAMA Oncology. The precancer in question, oral leukoplakia, "refers to a white plaque of variable cancer risk, having excluded other conditions, and affects up to 5% of the global population."  The authors of the study further caution that overtreatment of premalignant conditions is a concern, recommending that "evidence-based standards for adoption should be more stringent."

To read more about this study, click here. 

Sources mentioned: 

• Hanna GJ, Villa A, Nandi SP, et al. Nivolumab for Patients With High-Risk Oral Leukoplakia A Nonrandomized Controlled Trial. JAMA Oncol; Published online 16 November 2023. doi:10.1001/jamaoncol.2023.4853 
• Gyawali B, Strohbehn GW. Immunotherapy in Prepatients—Preventing or Promoting a Malignant Transformation? JAMA Oncol. Published online November 16, 2023. doi:10.1001/jamaoncol.2023.4799

Efficacy of rituximab maintenance in patients with mantle cell lymphoma who are MRD-negative after induction

 A recently completed elderly study of the European MCL (mantle cell lymphoma) network demonstrates the efficacy of "rituximab (R) - maintenance...in MRD (minimal residual disease) patients after R-CHOP induction [resulting in] substantially prolonged progression-free survival and overall survival."  Study authors also supported the need to advocate for MRD efficacy, thereby "establishing novel risk-adapted treatment strategies." 

To read more about this study, click here. 

Source mentioned: Hoster E, Delfau-Larue M-H, Macintyre E, et al. on behalf of the European MCL MRD Working Group and the European MCL Network. Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial. JCO; Published online 22 November 2023. DOI: 10.1200/JCO.23.00899

Incidence rates for most local and regional stage cancers declined during first year of COVID-19

 A new report, recently published in the International Journal of Cancer, indicates that during the first year of COVID-19, "cancer incidence rates declined for almost all cancer types."  While these findings, which also explored impact of COVID-19 pandemic on cancer incidence rates by stage at diagnosis, as well as race and ethnicity, can be attributed to suspension of healthcare during this time, study authors emphasize the importance of "strengthening the return to preventive care campaigns and outreach for detecting cancers at early and more treatable stages." 

To read more about this study, click here. 

Source mentioned: Schafer EJ, Islami F, Han X, Nogueira LM, Wagle NS, Yabroff KR, Sung H, Jemal A. Changes in cancer incidence rates by stage during the COVID-19 pandemic in the US. Int J Cancer. 2023 Nov 16. doi: 10.1002/ijc.34758. Epub ahead of print. PMID: 37971377.

Adding durvalumab to first-line platinum-based chemotherapy followed by maintenance durvalumab with or without olaparib improves PFS for patients with advanced or recurrent endometrial cancer

 Findings from DUO-E, "the first phase III study to examine the combination of immunotherapy and PARP inhibition in endometrial cancer" was recently presented at the European Society of Medical Oncology (ESMO) Congress.  The DUO-E study, consisting of 718 randomized patients, found statistically significant progress-free survival (PFS) when durvalumab, alone and in combination with olaparib, were used in the intent-to-treat population.  

To learn more about the DUO-E study, click here. 

Sources mentioned: 

• Westin SN, Moore K, Chon HS, et al. on behalf of the DUO-E investigators. Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial. JCO; Published online 21 October 2023. DOI: 10.1200/JCO.23.02132
• LBA41 - Westin SN, Moore KN, Chon HS, et al. Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva ± olaparib (ola) as a first-line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): Results from the phase III DUO-E/GOG-3041/ENGOT-EN10 trial. Ann Oncol 2023;34(Suppl_2):S1282–S1283. DOI: https://doi.org/10.1016/j.annonc.2023.10.035

NCI researchers develop approach that could help supercharge T-cell therapies against solid tumors

 Researchers at the National Cancer Institute (NCI) have recently presented findings on ways to improve effectiveness of T-cell immunotherapy treatment (namely CAR T-cell therapy) against solid tumours.   According to laboratory studies, "CAR and TCR T cells modified to express the cytokines IL-15 and IL-21 on their surface killed far more cancer cells than T cells carrying just one of these cytokines or neither of them."  This approach is a more targeted means of delivering the cytokines, thereby lessening severe or fatal side effects. 

Click here to learn more about the study, including listening to an audio soundbite and reading the radio transcript. 

New study shows people with advanced cancers more likely to use palliative care if providers are close to home

 A new study conducted by researchers at the American Cancer Society and presented at the American Society of Clinical Oncology annual symposium (October 27-28, 2023) has found that U.S. adults "with stage IV cancer living in nonmetropolitan, socioeconomically deprived areas, the southern U.S., or being treated at community facilities had lower accessibility to palliative care physicians than their counterparts in other areas."  The study, conducted on 333,000 adults with stage IV cancer in 2018-2019, found a correlation between geographic accessibility to palliative care providers and the timeliness of quality care received.   

To read more about thus study, click here. 

 

Adults living alone at higher risk for cancer mortality

 A recent study completed by researchers at the American Cancer Society (ACS) has shown that within the United States, adults living alone "were at a higher risk of cancer mortality in several sociodemographic groups, compared to adults living with others."  According to the report, led by principal scientist Dr. Hyunjung Lee at the ACS, 38 million households lived alone in 2022, compared to 7 million households in 1960.  Middle-aged adults (ages 45-64) "living alone had a 1.43 times higher [cancer mortality] risk" due in part to feelings of loneliness and social isolation.  

To read more about this study, click here. 

 

The potential of AI to improve cancer care is only going to grow

 The annual European Society of Medical Oncology (ESMO) annual conference, held in Madrid Spain from October 20-24, 2023 will contain dedicated sessions focused on the use of artificial intelligence (AI) in several aspects of cancer care, including: 

• use of AI technologies to improve early cancer detection and diagnosis 
• integration of AI into clinical workflows 
• use of AI to report real-world oncological data with accuracy and transparency 
• implementation of AI and digital oncology in routine practice 

To learn more about the AI sessions planned for the upcoming ESMO Conference, click here. 

Efficacy of dabrafenib plus trametinib in first-line treatment for children and adolescents with low-grade glioma with BRAF V600 mutations

 A recently completed randomized phase II study at the Hospital for Sick Children in Toronto indicates "superiority of dabrafenib plus trametinib as first systemic treatment for pediatric patients with low-grade glioma with BRAF V600 mutations as compared with carboplatin plus vincristine, the standard chemotherapy approach."  Following randomization amongst 110 patients, follow-up after a median of 18.9 months indicated overall response in 47% of patients treated with dabrafenib plus trametinib compared to a 11% overall response in those patients treated with chemotherapy.  Other benefits included longer progression-free survival and a lower rate of discontinuing treatment due to side effects. 

To learn more about this study, click here. 

Source mentioned: Bouffet E, Hansford JR, Garrè ML, et al. Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations. N Engl J Med 2023;389:1108-1120.

An alternative model for genetic testing delivery proposed with posttest counselling for those with pathogenic variants and on demand for those without pathogenic variants

 Findings from MAGENTA (Making Genetic Testing Accessible), the first randomized clinical study "evaluating the effect of individualized pretest and posttest counselling for cancer risk assessment while providing electronic enrolment, remote testing, and counselling" was recently published in JAMA Oncology.  

Of the 3839 women, ranging in age from 22-91 (average age: 44) included in the MAGENTA study, study authors concluded that alternative models of genetic counselling, such as telehealth, which became particularly prevalent during the COVID-19 pandemic, "provides more flexibility for patients and reduces costs."  

To learn more about the MAGENTA study, click here. 

Source mentioned:  Swisher EM, Rayes N, Bowen D, et al. Remotely Delivered Cancer Genetic Testing in the Making Genetic Testing Accessible (MAGENTA) Trial A Randomized Clinical Trial. JAMA Oncology; Published online 14 September 2023. doi:10.1001/jamaoncol.2023.3748

American Cancer Society announces new funding for hospital therapy dogs to support children with cancer and their families

The American Cancer Society recently expanded its PAWS (Pups Assisting with Support) program to six children's hospitals across the United States.  PAWS is a "pilot grant program that aims to improve the quality of life for hospitalized children with cancer through support from specially trained therapy dogs."  The $8000 funding grant for each of the hospitals participating in the program covers veterinary costs, adoption, training, food, grooming, beds, toys, and improving/maintaining dog facilities for a 12-month period.  Animal-assisted therapy for hospitalized children aids in decreasing anxiety, stress, depression, pain, as well as increasing quality of life.  

Click here to learn more about the PAWS program. 

  

Blog postings will resume week of September 25th

To all Grey Horizon readers, 

Please note that postings will resume the week of September 25th.   

Thank you, as always, for your continued support of this blog.  

First prospective description of familial EGFR-mutated lung cancer

A prospective cohort study, conducted at the Dana-Farber Cancer Institute in Boston has confirmed the existence "of an underappreciated syndrome of familial EGFR-mutated lung cancer predisposition which is characterized by development of lung adenocarcinomas harbouring an atypical spectrum of somatic EGFR mutations and high prevalence of lung nodules in germline carriers without a lung cancer diagnosis."   The study team further describes how cancer genomics has aided in the treatment of non-small cell lung cancer, including an understanding of inherited risk in lung cancer patients who have never smoked.  

To learn more about this study, click here. 

Source mentioned: Oxnard GR, Chen R, Pharr JC, et al. Germline EGFR mutations and familial lung cancer. JCO; Published online 14 August 2023. DOI: 10.1200/JCO.23.01372

Low incidence of local recurrence when omitting radiotherapy after breast-conserving surgery in Luminal A breast cancer

 The LUMINA study, conducted at the Juravinski Cancer Centre in Hamilton, Ontario, Canada, indicates that women 55 years or older "with T1N0, grade 1 or 2, luminal A breast cancer have a very low risk of local recurrence at 5 years after breast-conserving surgery when treated with endocrine therapy alone."  The authors of the study further concluded that clinicopathologic factors alone (including patient's age, size and grade of tumour), are of "limited use in the identification of patients at low risk of recurrence", where radiotherapy can be omitted. 

To read more about the LUMINA study, click here. 

Source mentioned: 

Whelan TJ, Smith S, Parpia S, et al. for the LUMINA Study Investigators. Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast Cancer. N Engl J Med 2023;389:612-619.

NCI unveils comprehensive proteogenomic dataset to help cancer researchers unravel molecular mysteries

 The National Institutes of Health (NIH) is releasing data, via the National Cancer Institute (NCI) "that standardizes genomic, proteomic, imaging, and clinical data from individual studies of more than 1,000 tumors across 10 cancer types."  The purpose of this pan-cancer proteogenomic dataset is to speed up cancer research via sharing of data, namely cancer mutations and protein modifications.  Proteomics data can be accessed via the Proteomic Data Commons at https://pdc.cancer.gov/pdc/cptac-pancancer. Genomic and transcriptomic data can be accessed via the Genomic Data Commons at https://portal.gdc.cancer.gov and the Cancer Data Service at https://dataservice.datacommons.cancer.gov/.

Sources mentioned: 

1. Li Y, Dou Y, Leprevost FDV, et al. Proteogenomic data and resources for pan-cancer analysis. Cancer Cell. August 14, 2023. DOI: 10.1016/j.ccell.2023.06.009.

2. Geffen Y, Anand S, Akiyama Y, et al. Pan-Cancer analysis of post-translational modifications reveals shared patterns of protein regulation. Cell. August 14, 2023. DOI: 10.1016/j.cell.2023.07.013.

3. Li Y, Dou Y, Leprevost FDV, et al. Pan-Cancer proteogenomics connects oncogenic drivers to functional states. Cell. August 14, 2023. DOI: 10.1016/j.cell.2023.07.014.

New study shows substantial racial and ethnic disparities among survivors of second primary cancers in the US

 A new study conducted by the American Cancer Society indicates that "non-Hispanic Black individuals diagnosed with a second primary cancer experienced 21% higher cancer-related death rates and 41% higher cardiovascular-related death rates compared [to] non-Hispanic White counterparts."  The findings further determined that Hispanic patents with a second primary cancer has a death rate 10% higher than non-Hispanic White patients.  According to lead study author Dr. Hyuna Sung, these rates were due, in part to Black and Hispanic patients being diagnosed with second primary cancer at a later stage.  

To read more about this study, click here.  

Study mentioned:  Sung H, Nisotel L, Sedeta E, Islami F, Jemal A. Racial and Ethnic Disparities in Survival Among People With Second Primary Cancer in the US. JAMA Netw Open. 2023;6(8):e2327429. doi:10.1001/jamanetworkopen.2023.27429

Machine learning model provides superior performance over specialist interpretations and could reliably predict metastatic disease in most patients with pheochromocytomas and paragangliomas

 A recently completed machine learning modelling study at the University Hospital Carl Gustav Carus in Dresden, Germany indicates that incorporating "plasma methoxytyramine in machine learning models, along with other clinical features such as primary tumour location and size, provides a highly accurate, non-invasive approach to predict metastases in patients with pheochromocytomas and paragangliomas", which can guide customized management and follow-up strategies for patients. The modeling study indicated that plasma methoxytyramine could identify metastatic disease "at sensitivities of 52% and specificities of 85%", with the highest-rated machine learning model encompassing nine features: plasma methoxytyramine, metanephrine, normetanephrine, age, sex, previous history of pheochromocytoma or paraganglioma, location and size of primary tumours, and presence of multifocal disease.  

To read more about this study, click here. 

Study mentioned: Pamporaki C, Berends AMA, Filippatos A, et al. Prediction of metastatic pheochromocytoma and paraganglioma: a machine learning modelling study using data from a cross-sectional cohort. The Lancet Digital Health; Published online 18 July 2023. DOI: https://doi.org/10.1016/S2589-7500(23)00094-8

Black cancer survivors face increased risk and mortality from heart disease; neighborhood socioeconomic status and insurance contributing factors

 A new report released by the American Cancer Society has found that "Black cancer survivors carry from 30% up to a three-fold higher mortality risk from cardiovascular disease", compared to White cancer survivors.  Notable racial differences were also observed in terms of neighborhood socioeconomic status and health insurance status, "explaining 12% to 31% of the excess cardiovascular death among Black versus White survivors." 

To learn more about this report, click here. 

Newly developed International Childhood Cancer Core Outcome Set represents physical, psychosocial, and neurocognitive outcomes for 17 common childhood cancer subtypes

 A recently completed International Childhood Cancer Outcome Project has resulted in the creation of 24 physical, psychosocial, and neurocognitive outcomes for childhood cancers. According to a joint international consensus statement created for measuring quality of survival among patients with childhood cancer, "most children and adolescents receiving modern cancer treatment survive at least 5 years beyond diagnosis...despite these promising results, survival rates remain poor for specific childhood, adolescent, and young adult cancer types."  The study authors also caution that patient and provider reports, together with frequent communication of results "are crucial facilitators for the adoption of these core sets in clinical practice and the subsequent initiation of quality improvement efforts." 

To read more about this study, click here. 

Study mentioned: van Kalsbeek RJ, Hudson MM, Mulder RL, … & the International Childhood Cancer Outcome Project participants. A joint international consensus statement for measuring quality of survival for patients with childhood cancer. Nature Medicine 2023;29:1340-1348.

Beginning the journey into the spirit world: First Nations, Inuit and Métis approaches to palliative and end-of-life care in Canada.

The Canadian Partnership Against Cancer (CPAC) recently launched Beginning the Journey into the Spirit World: First Nations, Inuit and Metis Approaches to Palliative and End-of-Life Care in Canada. This resource "summarizes factors contributing to palliative and end-of-life care experiences, highlights areas for action in palliative and end-of-life care based on priorities, gaps, challenges, and needs, and identifies innovative and Indigenous community-based models of care and person-centred approaches to palliative and end-of-life care" for First Nations, Inuit, and Metis Peoples and communities. 

To learn more about Beginning the Journal into the Spirit World, click here.   

Stopping treatment Is a reasonable strategy for patients with advanced NSCLC who are progression-free to front-line ICI at 2 years

 Recent findings from a retrospective cohort study conducted within the Division of Hematology and Oncology at the Perelman School of Medicine, University of Pennsylvania found no difference in overall survival between fixed 2-year vs. indefinite duration front-line treatment with immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.  Following extensive analysis of 1091 patients on ICI treatment 2 years after diagnosis, overall survival from 760 days was 79% in the fixed-duration group compared to 81% in the infinite duration group.  The study authors therefore determined there was no statistically significant difference in overall survival and thus determined that their study "supports treatment discontinuation at 2 years as a valid approach that does not appear to compromise survival outcomes." 

To read more about this study, click here. 

Sources mentioned: 

Sun L, Bleiberg B, Hwang W-T, et al. Association Between Duration of Immunotherapy and Overall Survival in Advanced Non–Small Cell Lung Cancer. JAMA Oncology; Published online 4 June 2023. doi:10.1001/jamaoncol.2023.1891

West H(J). Clinical Decision Making in the Real World—The Perfect as the Enemy of the Good. JAMA Oncology; Published online 4 June 2023. doi:10.1001/jamaoncol.2023.1811

An abnormal baseline geriatric 8 screening tool score strongly associates with increased long-term healthcare utilization in older patients with cancer

 A recent retrospective analysis conducted in the Department of General Medical Oncology at University Hospitals Leuven in Belgium indicates that "in the first 3 months after diagnosis of cancer in older patients, the healthcare utilization peaked, typically related to active cancer treatment, and then decreased in the time thereafter."  Healthcare utilization consisted of hospital admission, length of stay, visits to the emergency department, days in intensive care, appoints with general practitioners, home care, and transfers to nursing homes.  According to Professor Hans Wildiers, (General Medical Oncology, University Hospital Leuven, Belgium) "to optimize cancer treatment for older patients, it is important to identify frailty and underlying geriatric conditions at cancer diagnosis."   

To learn more about this study, click here. 

Source mentioned: 

Depoorter V, Vanschoenbeek K, Decoster L, et al. Long-term health-care utilisation in older patients with cancer and the association with the Geriatric 8 screening tool: a retrospective analysis using linked clinical and population-based data in Belgium. The Lancet Healthy Longevity; Published online 13 June 2023. DOI: https://doi.org/10.1016/S2666-7568(23)00081-8

Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine for the treatment of patients with locoregionally advanced nasopharyngeal carcinoma

The first randomized, controlled phase III trial assessing the efficacy and safety of adding adjuvant cisplatin-gemcitabine chemotherapy after concurrent chemoradiotherapy was recently unveiled at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.  The trial indicated "significant improvement in 3-year progression-free survival (PFS) compared with cisplatin-fluorouracil regimen in patients with locoregionally advanced nasopharyngeal carcinoma."  

To read more about this trial, click here. 

Sources mentioned: 

• Liu L-T, Liu H, Huang Y, et al. Concurrent chemoradiotherapy followed by adjuvant cisplatin–gemcitabine versus cisplatin–fluorouracil chemotherapy for N2–3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial. The Lancet Oncology; Published online 5 June 2023: DOI: https://doi.org/10.1016/S1470-2045(23)00232-2
• Yip PL, Lee AWM, Chua MLK. Adjuvant chemotherapy in nasopharyngeal carcinoma. The Lancet Oncology; Published online 5 June 2023: DOI: https://doi.org/10.1016/S1470-2045(23)00266-8
• Tang L-Q, Liu L-T, Liu H, et al. Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial. J Clin Oncol 41, 2023 (suppl 16; abstr 6000).

Blog postings will resume week of June 19th

To all Grey Horizon readers, 

Please note that postings will resume the week of June 19th.   

Thank you, as always, for your continued support of this blog.  

New studies presented at 2023 ASCO annual meeting ties loneliness and major financial event to cancer diagnoses and higher mortality risk

 New studies unveiled at the 2023 annual meeting of the American Society of Clinical Oncology (ASCO), held in Chicago from June 2-6, 2023, indicate loneliness and experiencing a major financial event as direct correlations to a cancer diagnosis and higher mortality risk.  

Led by Jingxuan Zhao, senior associate scientist of health services research at the American Cancer Society, cancer survivors 50 years and older reported "elevated loneliness scores [and] had higher hazard ratios, indicating higher mortality risks."  These findings occurred even after adjusting for sociodemographic characteristics, leading to strong recommendations to implement programs to screen for loneliness among cancer survivors and provide social support. 

An additional study unveiled at the ASCO annual meeting indicates that 1/3 of cancer patients experienced a major adverse financial event (AFE), such as bankruptcy, lien, or eviction, prior to being diagnosed with cancer, and were subsequently diagnosed at a later cancer stage.  Of the 101,649 patients studied, 32.6% had a major AFE before being diagnosed, most commonly among non-Hispanic Black, unmarried, and low-income patients.  However, "even 27% of patients in the highest income group had an AFE prior to diagnosis."  

To learn more about these studies, click here and here. 

Use of immune checkpoint inhibitors safe and effective in cancer patients with HIV and on antiretroviral therapy

 A recently conducted retrospective study by the Cancer Therapy Using Checkpoint Inhibitors in People Living with HIV-International (CATCH0IT) Consortium determined that immune checkpoint inhibitors were found to be safe and had "differential activity across tumour types."  CATCH-IT enrolled 390 cancer patients with HIV into their cohort, "who received anti-PD-1 or anto-PD-L1 therapies and evaluated the safety and activity." This cohort was unique, as patients with HIV are at higher risk for developing cancer, due to dysfunctional immune systems.   The 3 most common cancer identified in the cohort included non-small-cell lung cancer (28%), hepatocellular carcinoma (11%), and head and neck squamous cell carcinoma (10%).  While the study authors acknowledged the relatively small sample size for this study, the results do support "the growing body of evidence [among] the use of ICIs [in] patients with HIV to enhance their inclusion in clinical studies." 

To read more about this study, click here.

Source mentioned: 

El Zarif T, Nassar AH, Adib E, et al. Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium. JCO; Published online 16 May 2023. DOI: 10.1200/JCO.22.02459

New study shows mortality rates for most cancers decreasing globally, except liver cancer in men and lung cancer in women increasing

A new study conducted by the American Cancer Society has found a downward trend in mortality rates for major cancers worldwide, with the exception of liver cancer in men and lung cancer in women.  According to Dr. Ahmedin Jemal, senior author of the study, "these findings reinforce the importance of strengthening the health systems not only in resource-limited countries but also in high-income countries across the world for broad and equitable implementation of known cancer prevention and control interventions."   24 countries in the study reported higher mortality rates from lung cancer in women, with the highest increase noted in Spain (4.3%), Uruguay (3.7%), and Greece (3.2%).  For men, highest increases in liver cancer were found in Ireland (5.8%), Norway (5.3%), and Malta (4.8%), increases which have been attributed to hepatitis C infection, and nonviral etiology, including obesity, diabetes, and heavy alcohol consumption.  

To read more about this study, click here. 

ESMO launches living guidelines to enhance the usability in routine cancer patient care

 A recent press release from the European Society of Medical Oncology (ESMO) announces the release of the ESMO Living Guidelines, "a new tool designed to make [guidelines] easier to use in oncologists' routine clinical practice and support optimal decision-making in a rapidly evolving medical field." The guidelines provide an overview of patient management, including decision-making algorithms and key recommendations; they are to be considered a supplement to the ESMO Clinical Practice Guidelines, which remain the key "reference source for the optimal management of each tumour type and disease setting."  

To read more about these guidelines, click here.